# ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05405595/  
OnCo record `nct05405595` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ADG126, Pembrolizumab, Bevacizumab, Trifluridine/tipiracil and Fruquintinib in advanced solid tumours, run by Adagene Inc, now recruiting.

## Summary

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05405595 by Adagene Inc, with 186 participants planned, started 2022-06-15 and due to reach its primary completion in 2026-10-31. Interventions recorded: ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab) and Standard of care (Fruquintinib).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05405595
- Phase: 1/2
- Setting: A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors
- Sponsor: Adagene Inc
- Enrolled: 186

## Sources

- ClinicalTrials.gov NCT05405595: https://clinicaltrials.gov/study/NCT05405595

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ADG126](https://onco.cc/drugs/adg126/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct05405595.json